Delivery Order SPE2DB22D1106-SPE2DB25FEZA2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a $11,625.10 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This firm fixed-price contract represents a non-competitive set-aside delivery against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the contractor's corporate office location in...
- The Defense Logistics Agency awarded a $2,565.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $7,202.90 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Vyvanse 70 mg capsules (100-count units) valued at $3,496.33 with a firm fixed price structure. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,769.46 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical products will be delivered to...
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEZA2Delivery Order
The Defense Logistics Agency awarded a $7,598.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a non-set-aside competitive award with performance completion scheduled for July 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999 through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems through its extensive portfolio of brand-name and generic medications. The DLA Troop Support Medical IDC enables the company to supply a broad range of pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. This particular delivery order for Vyvanse, a controlled stimulant medication used in treating attention-deficit/hyperactivity disorder, exemplifies the company's role in providing specialty pharmaceuticals essential to military medical operations and readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 7/22/25 |